Form 4: Acrivon Therapeutics Insider Sells Shares
Insider Transaction (Form 4)
Peter Blume-Jensen and 1 other reported changes in beneficial ownership of Acrivon Therapeutics, Inc. common stock on August 18, 2026.
Summary
- Open-market sale: disposed of 1,229 Common Stock at $2.01 ($2,470) on August 18, 2026; holds 2,244,088 after (Direct).
- Open-market sale: disposed of 484 Common Stock at $2.01 ($973) on August 18, 2026; holds 385,859 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $3,443 of stock on the open market.
Insider Transactions
Peter Blume-Jensen — Director, Officer (President and CEO)
Kristina Masson — Director, Officer (EVP - Business Operations)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-18 | Open-market sale | Common Stock | 1,229 | $2 | $2.5K | 2,244,088 |
| 2026-08-18 | Open-market sale | Common Stock | 484 | $2 | $973 | 385,859 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-18 | Open-market sale (1,229 shares) |
| 2026-08-18 | Open-market sale (484 shares) |
Keywords
insider transaction, Form 4, ACRV, Acrivon Therapeutics, Inc., bearish, Peter Blume-Jensen, Kristina Masson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.